Complete guide
Tirzepatide: The Complete Guide
Tirzepatide is a once-weekly injectable that activates both GIP and GLP-1 receptors. It is FDA approved as Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity, and as Mounjaro for type 2 diabetes. In SURMOUNT-1 it produced about 20.9% mean weight reduction at 15 mg over 72 weeks. Compounded tirzepatide is a separate, non-approved product that has never been studied in a randomised trial.
Key takeaways
- Tirzepatide is a dual GIP/GLP-1 receptor agonist given once weekly by subcutaneous injection.
- Zepbound is the weight-management brand; Mounjaro is the type 2 diabetes brand — same molecule, different indication.
- SURMOUNT-1 recorded about 20.9% mean weight reduction at 15 mg; SURMOUNT-2 recorded less in people with diabetes.
- Stopping produces substantial regain (SURMOUNT-4), so it functions as long-term treatment.
- Compounded tirzepatide is not FDA approved and has no randomised evidence of its own.
| Drug class | Dual GIP and GLP-1 receptor agonist |
|---|---|
| Administration | Subcutaneous injection, once weekly |
| Approved brands | Zepbound (weight management; obstructive sleep apnoea), Mounjaro (type 2 diabetes) |
| Labelled dose range | 2.5 mg starting, escalating to a maximum of 15 mg weekly |
| Pivotal weight trial | SURMOUNT-1 — about 20.9% at 15 mg, N=2,539 |
| Compounded status | Not FDA approved; no randomised trial |
What is tirzepatide and how is it different from other GLP-1 drugs?
Tirzepatide activates two incretin receptors rather than one. Semaglutide and liraglutide act on the GLP-1 receptor alone; tirzepatide acts on both GLP-1 and GIP receptors. This dual action is the leading explanation for the larger average weight reduction seen in its trials, and it is why tirzepatide is sometimes described as a dual agonist rather than a GLP-1 drug.
Practically, the effects a patient notices are similar in kind — reduced appetite, earlier fullness, slower gastric emptying — but larger in degree. The head-to-head SURMOUNT-5 trial confirmed greater weight and waist reduction than semaglutide at 72 weeks.
What does the evidence actually show?
The pivotal obesity trial, SURMOUNT-1, randomised 2,539 adults without diabetes to 5, 10, or 15 mg weekly or placebo for 72 weeks and recorded mean weight reduction up to about 20.9% against 3.1% on placebo. SURMOUNT-2 studied adults who also had type 2 diabetes and recorded meaningfully less, roughly 12.8% to 14.7%.
SURMOUNT-4 answered the maintenance question by randomising people who had already lost weight to continue or switch to placebo: continuing held the loss, stopping produced substantial regain.
| Trial | Population | N | Result | Identifiers |
|---|---|---|---|---|
| SURMOUNT-1 | Adults with obesity or overweight, without type 2 diabetes | 2,539 | Mean weight reduction up to about 20.9% at 15 mg vs 3.1% placebo | NCT04184622 · PMID 35658024 · DOI |
| SURMOUNT-2 | Adults with obesity or overweight AND type 2 diabetes | 938 | Mean weight reduction about 12.8% to 14.7% vs 3.2% placebo | NCT04657003 · PMID 37385274 · DOI |
| SURMOUNT-4 | Adults with obesity or overweight, without type 2 diabetes | 670 | Continued treatment maintained and modestly extended weight loss; withdrawal to placebo produced substantial regain | NCT04660643 · PMID 38078870 · DOI |
| SURMOUNT-5 | Adults with obesity or overweight with a weight-related comorbidity, without diabetes | 751 | Tirzepatide superior to semaglutide for weight and waist circumference at week 72 (waist -18.4 cm vs -13.0 cm) | NCT05822830 · PMID 40353578 · DOI |
Who is tirzepatide for?
Under its approved labelling, Zepbound is indicated for chronic weight management in adults meeting BMI criteria with or without a weight-related comorbidity, and Mounjaro for glycaemic control in type 2 diabetes. Eligibility is a clinical judgement that also weighs contraindications — including a personal or family history of medullary thyroid carcinoma or MEN2 — and other medications.
This site does not assess eligibility or recommend a dose. Those determinations require a prescriber with access to your history.
What does treatment cost and why is that hard to answer?
Brand pricing, insurance coverage, manufacturer savings programmes, and compounded alternatives produce wildly different figures, and telehealth providers frequently advertise a medication price while billing membership, consultation, or shipping separately. The number that matters is the recurring cost after every mandatory fee, sustained over the years that maintenance implies.
This site normalises provider pricing before comparing it — see the cost hub and the true-cost calculator.
What the evidence shows
- Large mean weight reduction at labelled doses in randomised trials.
- A dose-response relationship across the studied 5-15 mg range.
- Superiority to semaglutide on weight and waist in a head-to-head trial.
- Substantial regain after randomised withdrawal.
What the evidence does not show
- That compounded tirzepatide performs equivalently — it has never been tested.
- That every individual achieves the trial mean.
- That a dose below the studied range produces proportional benefit.
- That weight outcomes alone establish cardiovascular benefit.
- Trial populations exclude many comorbidities, so real-world results commonly fall short of trial means.
- All pivotal trials were sponsored by the manufacturer, which is disclosed on each trial page.
- Long-term data beyond the trial windows is still accumulating.
Related: How it works · Side effects · Cost · Compounded tirzepatide
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
Why does the dual mechanism matter in practice?
The practical consequence of activating two receptors rather than one is not a different kind of effect but a larger one. Patients describe the same experience reported with single-agonist drugs — food becomes less interesting, portions that once felt normal feel excessive, and the mental preoccupation with eating that many people describe as constant background noise quietens. What differs is degree, and the head-to-head trial quantified it rather than leaving it to inference.
There is a second, less discussed consequence. Some evidence suggests GIP receptor activity moderates nausea signalling, which would help explain why the head-to-head trial recorded lower gastrointestinal discontinuation for tirzepatide than for semaglutide despite tirzepatide producing greater weight reduction. That combination — more effect and fewer treatment-ending side effects — is unusual, and it is the strongest argument in the drug's favour that does not depend on the weight number alone.
None of this transfers automatically to a compounded preparation. The mechanism belongs to the molecule, but the effect belongs to the dose that actually reaches the bloodstream, and that depends on concentration accuracy, formulation, and stability that are verified for an approved product and not independently verified for a compounded one.
What does the drug not do?
Tirzepatide does not increase energy expenditure to any degree that explains its effect. The dominant mechanism is reduced energy intake through appetite suppression and delayed gastric emptying, which matters because it sets a realistic expectation: the drug makes eating less feel manageable rather than making the body burn more.
It does not act on the psychological drivers of eating in any targeted way, though many people report that reduced food preoccupation makes those drivers easier to address. It does not build the habits that support weight maintenance, which is why the trials studied it alongside diet and physical activity rather than instead of them. And it does not produce a durable change that persists after withdrawal, which SURMOUNT-4 established directly.
Being clear about the boundary is not a criticism of the drug. It is what allows a person to plan — for the cost of continued treatment, for the behavioural work that continues alongside it, and for the possibility that they will want to stop at some point and should understand what follows.
How should someone weigh this decision?
The decision is genuinely individual, and it involves at least four separate questions that often get collapsed into one. Whether the drug is clinically appropriate is a prescriber's judgement about indication, contraindications, and interacting medication. Whether it is likely to work well for a given person is a probabilistic question the trials inform but cannot answer individually. Whether it is affordable depends on coverage and on the recurring rather than introductory price. And whether it is the right time depends on circumstances the evidence says nothing about.
What the evidence does support is that the decision should be framed as entering long-term treatment for a chronic condition, not as a course with a finish line. Framing it as a course leads predictably to disappointment when treatment stops and weight returns, and to the mistaken conclusion that the person failed rather than that the treatment ended.
What does this page cover, and what does it deliberately leave out?
This page addresses Mechanism, approvals, evidence, safety, cost and access and compounded distinctions, organised around the primary question of tirzepatide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Mechanism | Covered on this page | Primary evidence |
| Approvals | Covered on this page | Primary evidence |
| Evidence | Covered on this page | Primary evidence |
| Safety | Covered on this page | Primary evidence |
| Cost | Covered on this page | Primary evidence |
| Access and compounded distinctions | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 14 technical terms this page uses, including DOI, GIP, GLP-1, MEN2 — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| MEN2 | Multiple endocrine neoplasia syndrome type 2. An inherited condition that predisposes to medullary thyroid carcinoma, and a labelled contraindication to tirzepatide. |
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| contraindication | A circumstance in which a drug should not be used at all. For tirzepatide these include a personal or family history of medullary thyroid carcinoma and MEN2. |
| dual agonist | A drug that activates two distinct receptors. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is why describing it simply as a GLP-1 drug is imprecise. |
| gastric emptying | The rate at which food leaves the stomach. Incretin therapies slow it, which prolongs fullness and is also the mechanism behind much of the nausea and the perioperative aspiration concern. |
| incretin | A gut hormone released in response to food that amplifies insulin secretion. GIP and GLP-1 are the two principal human incretins, and the drug class that mimics them is named after them. |
| medullary thyroid carcinoma | A form of thyroid cancer with a strong hereditary component. A personal or family history of it is a labelled contraindication to tirzepatide. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised withdrawal | A design in which everyone first receives the active drug, and only those who respond are then randomised to continue or stop. SURMOUNT-4 used this design, which is why its regain finding cannot be explained away by differences between groups. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
What is tirzepatide?
A once-weekly injectable that activates both GIP and GLP-1 receptors, approved as Zepbound for weight management and Mounjaro for type 2 diabetes.
How much weight can you lose on tirzepatide?
About 20.9% mean reduction at 15 mg over 72 weeks in SURMOUNT-1, and roughly 12.8-14.7% in people with type 2 diabetes in SURMOUNT-2.
Is tirzepatide better than semaglutide?
In the head-to-head SURMOUNT-5 trial it produced greater weight and waist reduction. Drug choice still depends on tolerance, indication, coverage, and cost.
Is compounded tirzepatide the same drug?
It contains the same molecule but is not FDA approved, may differ in concentration and formulation, and has never been studied in a randomised trial.
Do you have to stay on tirzepatide permanently?
SURMOUNT-4 found substantial regain after stopping, so maintaining results generally means continued treatment. Stopping is an individual clinical decision.
What are the most common side effects?
Gastrointestinal effects — nausea, diarrhoea, vomiting, constipation — mostly mild to moderate and concentrated during dose escalation.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.